Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL5149506 | 0.81 | ADH5 (0.43) | TSHRFAAHMGLLCYP24A1NAPRT | |
| SCHEMBL446876 | 0.80 | — | — | |
| SCHEMBL10969757 | 0.78 | PTGS2 (0.51) | ALDH1A1TBXAS1KMT2A | |
| Hydrochloric Acid SCHEMBL5149348 | 0.78 | MAPT (0.36) | FAAHMGLLCYP24A1ALDH1A1LMNA | |
| Salicylic Acid SCHEMBL5149483 | 0.77 | ALDH1A1 (0.49) | TSHRSMN1; SMN2FAAHMGLLCYP24A1 | |
| 1-Methylimidazole SCHEMBL17961221 | 0.76 | TSHR (0.53) | TSHRSMN1; SMN2NAPRTACP1ALDH1A1 | |
| SCHEMBL27803172 | 0.73 | TSHR (0.53) | TSHRSMN1; SMN2NAPRTACP1ALDH1A1 | |
| SCHEMBL2457493 | 0.72 | TSHR (0.48) | TSHRSMN1; SMN2TBXAS1 | |
| SCHEMBL17961167 | 0.72 | TSHR (0.41) | TSHRSMN1; SMN2FAAHMGLLCYP24A1 | |
| SCHEMBL27810405 | 0.71 | SMN1; SMN2 (0.67) | TSHRSMN1; SMN2NAPRTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539707-A4 | METHOD AND COMPOUNDS FOR PROMOTING HEALING AND REDUCING INFLAMMATION | BIODIEM LTD (AU) | 2007-05-30 | — | — | EP | claimed |
| EP-1539707-A1 | METHOD AND COMPOUNDS FOR PROMOTING HEALING AND REDUCING INFLAMMATION | Biodiem Ltd. (AU) | 2005-06-15 | — | — | EP | claimed |
| WO-2004013108-A1 | METHOD AND COMPOUNDS FOR PROMOTING HEALING AND REDUCING INFLAMMATION | BIODIEM LIMITED (AU) | 2004-02-12 | — | — | WO | claimed |
| EP-1539707-A4 | METHOD AND COMPOUNDS FOR PROMOTING HEALING AND REDUCING INFLAMMATION | BIODIEM LTD (AU) | 2007-05-30 | — | — | EP | disclosed |
| US-20060135587-A1 | Method and compounds for promoting healing and reducing inflammation | BIODIEM, LTD. (AU) | 2006-06-22 | — | — | US | disclosed |
| EP-1539707-A1 | METHOD AND COMPOUNDS FOR PROMOTING HEALING AND REDUCING INFLAMMATION | Biodiem Ltd. (AU) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004013108-A1 | METHOD AND COMPOUNDS FOR PROMOTING HEALING AND REDUCING INFLAMMATION | BIODIEM LIMITED (AU) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135587-A1 | Method and compounds for promoting healing and reducing inflammation | IL1B, MIF, ALKBH5 | TSHR 4776/4885SMN1; SMN2 2994/4885FAAH 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.